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OBJECTIVES: Deferasirox is a recently approved once-daily
oral chelator that has been shown to produce reductions in liver
iron concentrations and serum ferritin similar to those with infu-
sional deferoxamine. The cost-effectiveness of deferasirox vs
deferoxamine in b-thalassemia major patients have has not been
examined. METHODS: A Markov model was used to estimate
the total additional lifetime costs and quality-adjusted life years
(QALYs) gained with deferasirox versus deferoxamine in
patients with b-thalassemia major and chronic iron overload
from blood transfusions. Patients were assumed to receive pre-
scribed dosages of deferasirox and deferoxamine that have been
shown to be similarly effective in such patients. Compliance with
deferoxamine as well as costs of deferoxamine administration
and complications of iron overload were based on analyses of
health insurance claims data of transfusion-dependent tha-
lassemia patients. Probabilities of complications of iron overload
and death by level compliance with chelation were estimated
using data from published studies. Because data on compliance
with deferasirox in typical clinical practice are unavailable, we
used published data on compliance with the oral chelator
deferiprone vs deferoxamine. Utilities (weights representing
patient quality of life) were based on a study of patient prefer-
ences for oral vs infusional chelation therapy, as well as pub-
lished literature and assumption. A US healthcare system
perspective was employed. RESULTS: Deferasirox results in a
gain of 3.9 QALYs per patient at an additional expected lifetime
cost of $133,321 per patient. Cost-effectiveness is $33,792 per
QALY gained. Cost-effectiveness is sensitive to the estimated
costs of deferoxamine administration and the quality of life
beneﬁt associated with oral vs infusional therapy and is more
favorable in younger patients. CONCLUSIONS: The cost-
effectiveness of deferasirox vs deferoxamine in patients with
transfusion-dependent b-thalassemia is within the range 
considered generally-accepted in the United States.
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OBJECTIVES: Patients with high-risk acute lymphoblastic
leukemia (ALL), including Philadelphia chromosome positive
(Ph+) ALL, typically have extremely poor prognosis, experience
poor quality of life (QoL) and incur high economic cost. This
study examined the economic and humanistic outcomes for high-
risk ALL. METHODS: A systematic search of the English-
language literature published between 1990 and 2005 was 
conducted. Additional searches were conducted from the
retrieved article bibliographies and appropriate conference 
proceedings (2000–2005). Articles selected for inclusion were
prospective or retrospective studies speciﬁcally designed to
examine burden of illness, direct medical costs, cost drivers, 
or QoL outcomes of ALL and treatments. RESULTS: Of 798
abstracts screened, 106 met selection criteria and were reviewed
in detail. Forty-nine and 47 studies focused on the economics
and QoL aspects of ALL, respectively. The average annual direct
medical cost per high-risk ALL patient ranged from $100,000 to
$136,000. Hospitalization was the major cost component com-
prising 50%–80% of total direct costs. Major hospital cost
drivers included infections, chemotherapy, growth factors, trans-
fusions, and transplantation. These drivers resulted in more fre-
quent hospitalizations and longer ICU lengths of stay for high
risk patients. High-risk ALL patients typically had psychological
problems and physical complaints, especially in domains of
emotion, cognition, and pain. Furthermore, high-risk patients
were more likely to have poorer QoL than standard-risk patients
due to higher relapse rates and increased need for transplanta-
tion. CONCLUSIONS: ALL exacts a substantial economic and
humanistic burden on patients, their loved ones and society in
general. This burden appears particularly heavy for high-risk
patients, such as Ph+ ALL. Imatinib, a molecularly targeted
therapy, has been reported to prolong disease-free-survival in
Ph+ ALL with good tolerability in clinical studies. Research is
warranted to evaluate the economic and humanistic beneﬁts of
imatinib as compared to the current therapies in the treatment
of Ph+ ALL.
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OBJECTIVES: To compare the cost of treatment for three “on-
demand” treatment regimens using recombinant activated Factor
VII (rFVIIa [NovoSeven®]) and activated prothrombin-complex
concentrate (APCC [FEIBA® VH]) for home treatment of minor-
to-moderate bleeds in hemophilia with inhibitors. METHODS:
A decision analytic model was developed from the payer’s 
perspective to calculate the projected cost per bleeding episode
and the 1-year cost of treatment for three “on-demand” 
treatment strategies consisting of ﬁrst, second, and third-line
treatments: rFVIIa/rFVIIa/rFVIIa, APCC/rFVIIa/rFVIIa, and
APCC/APCC/rFVIIa. Published literature was used to deﬁne
treatment algorithms, number of bleeds, dosing, costs, efﬁcacy,
and re-bleeds. Evaluable bleeds controlled with rFVIIa and
APCC ranged from 88–93% and 78–81%, respectively. Number
of bleeds was assumed to be 15 per year (range 10–20). Drug
costs were based on 2005 U.S. average wholesale prices; other
direct medical costs reﬂected 2005 values. Univariate and prob-
abilistic sensitivity analyses (PSA) were conducted on key vari-
ables to ascertain model robustness. RESULTS: The cost per
bleed (and 1-year cost of treatment) per patient was $28,076
($421,137), $30,883 ($463,251), and $32,150 ($482,253) 
using rFVIIa/rFVIIa/rFVIIa, APCC/rFVIIa/rFVIIa, and APCC/
APCC/rFVIIa, respectively. Annual cost offsets ranging from
$42,115–$61,116 per patient occurred for the rFVIIa-only
regimen through avoidance of second and third lines of treat-
ment. Univariate sensitivity analyses showed consistent results
with the base case. In PSA, the rFVIIa-only strategy was less
expensive than either alternative in 68% of 10,000 model sim-
ulations. CONCLUSIONS: The management of minor-to-
moderate bleeds extends beyond the initial line of treatment, and
should include the economic impact of rebleeding over multiple
lines of therapy. The annual cost of treatment for minor-
